Carmed Pharmaceuticals Publishes Second Peer-Reviewed Study in 2026, Bolstering Scientific Evidence for Its Formulations

Carmed Pharmaceuticals, a research-driven company specializing in standardized carvacrol-based formulations, is highlighting the publication of a new peer-reviewed scientific study involving two of its flagship formulations, Vacrol® and S-Mix®. The research, recently published in the journal Antioxidants, represents the second peer-reviewed publication in 2026 involving Carmed formulations, further reflecting the company’s long-term commitment to scientific investigation, formulation development, and academic collaboration.

The study evaluated Vacrol® and S-Mix® in a series of laboratory and preclinical experimental models, examining formulation characteristics, biological activity, and antimicrobial properties. Researchers concluded that the formulations demonstrated distinct biological profiles and warranted further mechanistic and translational investigation.

Unlike many wellness companies that focus primarily on product marketing, Carmed Pharmaceuticals has invested heavily in scientific collaboration and research surrounding its proprietary formulations. The newly published paper follows a January 2026 peer-reviewed study published in Plants that also evaluated Carmed formulations in experimental models. Together, the publications contribute to a growing body of scientific literature examining standardized carvacrol-based formulations and their biological properties.

“Scientific inquiry has always been central to our philosophy,” said Mustafa Can, Founder of Carmed Pharmaceuticals. “We believe meaningful innovation requires ongoing research, independent evaluation, and a willingness to explore important scientific questions through rigorous study.” The company emphasizes that the published research reflects scientific investigation into formulation science and biological mechanisms and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.

Carmed’s development approach focuses on standardized botanical formulations designed around reproducibility, analytical validation, and quality control. The company collaborates with researchers, laboratories, healthcare institutions, and scientific advisors as part of its broader research ecosystem. “Research is not a marketing exercise for us,” said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. “We view scientific publication as an important part of transparency and long-term credibility. Our goal is to continue contributing to the scientific conversation while making our formulations more accessible to consumers.”

The publication comes as Carmed continues its expansion into the United States market. Several Carmed formulations, coming soon to Amazon, are now available to U.S. consumers through OneLavi.com, including Vacrol® Kids Spray, S-Mix®, Vacrol® Capsule, and Vacrol-M® Capsule. According to the company, expanding retail availability alongside continued scientific publication reflects Carmed’s broader strategy of combining research, quality-focused formulation development, and long-term brand building as it establishes its presence in the U.S. market.

This news story relied on content distributed by Newsworthy.ai. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Carmed Pharmaceuticals Publishes Second Peer-Reviewed Study in 2026, Bolstering Scientific Evidence for Its Formulations.

The post Carmed Pharmaceuticals Publishes Second Peer-Reviewed Study in 2026, Bolstering Scientific Evidence for Its Formulations appeared first on citybuzz.